BioLineRx Reports Third Quarter 2020 Financial Results and Provides Corporate Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. WDC
3. DECK
4. BYD
5. WCN
6. SPOT
7. BMY
8. FIX
9. TSCO
10. BE

Go back to BioLineRx Reports Third Quarter 2020 Financial Results and Provides Corporate Update

BioLineRx (BLRX) Tops Q3 EPS by 33c

November 23, 2020 7:02 AM EST

BioLineRx (NASDAQ: BLRX) reported Q3 EPS of ($0.02), $0.33 better than the analyst estimate of ($0.35).

"The past several months have been very exciting for BioLineRx, highlighted by the very positive result of the interim analysis of our Phase 3 GENESIS study in stem cell mobilization" stated Philip Serlin, Chief Executive Officer of BioLineRx. "A statistically significant benefit in the primary endpoint was observed by combining motixafortide with the standard of care, G-CSF, leading the DMC to recommend that we cease study enrollment at 122 patients, instead of the 177 originally planned. We look forward to... More